Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis

• Published in: Cancer medicine (Malden, MA) Vol. 9; no. 17; pp. 6216 - 6224
• Main Authors: Sadetsky, Natalia, Hernandez, Alexandra, Wallick, Chris J., McKenna, Edward F., Surinach, Andy, Colburn, Dawn E.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.09.2020; John Wiley and Sons Inc; Wiley
• Subjects: Age; Cancer therapies; Central nervous system; Chemotherapy; Clinical Cancer Research; CNS metastases; Comorbidity; Cytotoxicity; Demographics; Diabetes; Disease; Heart attacks; Immunotherapy; Medical diagnosis; Medical prognosis; Medicare; Melanoma; Metastases; Metastasis; Nervous system; Original Research; overall survival; Patients; Population; Radiation therapy; Radiosurgery; radiotherapy; Skin cancer; Survival; systemic treatment; United States > US; CNS metastases; overall survival; radiotherapy; melanoma; systemic treatment
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.3256

Background Central nervous system (CNS) metastasis is common in advanced melanoma patients. New treatment options have improved overall prognosis, but information is lacking for patients with CNS metastases. We investigated treatment patterns and survival outcomes in older melanoma patients with and without CNS metastases. Methods A retrospective analysis of SEER‐Medicare, a population‐based linked database, was undertaken in patients aged > 65 years with advanced melanoma diagnosed from 2004 to 2011 and followed until 2013. Results A total of 2522 patients were included. CNS metastases were present in 24.8% of patients at initial metastatic diagnosis; 16.5% developed CNS metastases during follow‐up. Chemotherapy was the most common treatment regardless of CNS metastases. Overall survival (OS) was better for patients without CNS metastases (median, 9.5 months; 95% confidence interval [CI], 8.8‐10.2) vs patients with CNS metastases (3.63 months; 95% CI, 3.4‐3.9). Among patients with CNS metastases, median OS for targeted therapy, immunotherapy, and chemotherapy was 6 (95% CI, 2.5‐9.6), 5.5 (95% CI, 3.8‐7.5), and 4.5 (95% CI, 3.8‐5.4) months, respectively, vs 2.4 (95% CI, 2.1‐2.7) and 2.1 (95% CI, 1.8‐2.7) months for local radiotherapy and no treatment, respectively. Stereotactic radiosurgery demonstrated higher OS vs whole‐brain radiation therapy (median, 4.98 [95% CI, 3.5‐7.5] vs 2.4 [95% CI, 2.1‐2.7] months). Conclusion Patients with CNS metastases from melanoma remain a population with high unmet medical need despite recent advances in treatment. Systemic treatments (eg, BRAF‐targeted therapy and immunotherapy) and stereotactic radiosurgery demonstrated meaningful but modest improvements in OS. Further explorations of combinations of radiotherapy, BRAF‐targeted therapies, and immunotherapies are needed. This retrospective, population‐based analysis of older patients with advanced melanoma demonstrated that patients with central nervous system (CNS) metastases have limited treatment options and poor survival outcomes. Improved survival was observed for patients with CNS metastases treated with BRAF‐targeted therapy or immunotherapy, but significant unmet medical need remains.